PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 152 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $1,330,000 | -94.4% | 350,000 | -93.9% | 0.08% | -95.5% |
| Q4 2018 | $23,940,000 | -38.0% | 5,700,000 | -7.4% | 1.81% | -21.7% |
| Q3 2018 | $38,611,000 | +89.4% | 6,158,000 | +142.8% | 2.32% | +74.2% |
| Q2 2018 | $20,389,000 | +13.9% | 2,536,000 | +5.7% | 1.33% | -2.8% |
| Q1 2018 | $17,904,000 | +160.8% | 2,400,000 | +109.1% | 1.37% | -55.0% |
| Q1 2015 | $6,865,000 | – | 1,148,000 | – | 3.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
| TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
| Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
| TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
| EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
| Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
| TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
| FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
| Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
| OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |